Advertisement

Pegylated Interferons: Clinical Applications in the Management of Hepatitis C Infection

  • S. James Matthews
  • Christopher McCoy

Keywords

Sustained Virological Response Sustained Virological Response Rate African American Early Virological Response Rapid Viral Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abi-Nassif, S., Mark, E.J., Fogel, R.B., Hallisey, R.K., Jr. (2003). Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest, 124: 406–410.PubMedGoogle Scholar
  2. Afdhal, N.H., Dieterich, D.T., Pockros, P.J. (2004). Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double blind, randomized controlled study. Gastroenterology, 126: 1302–1311.PubMedGoogle Scholar
  3. Afdhal, N., Jacobson, I., Brown, R., Freilich, B., Santoro, J., Griffel, L., Bass C. (2006). The effect of liver fibrosis and cirrhosis on SVR in 4913 patients with hepatitis C: Results from the Win-R trial. Gastroenterology, 130 (4 Suppl 2): A-771; abstract 655.Google Scholar
  4. Ahmed, F., Jacobson, I.M., Chen, S.T., Cofrancesco, S., Cooley, J., Demicco, M., Freilich, B., Hudes, B., Jensen, J., Levin, A., Lyche, K., McCone, J., Monsour, H.P., Peine, C., Pimstone, N., Rosenfield, T., Strauss, R., Stokes, K., Terrault, N., Tsai, N., Wasserman, R.B., Woolf, G.M., Brown, R.S., Brass, C. (2003). Serious ophthalmologic events during pegylated interferon and ribavirin therapy for chronic hepatitis C: Observations from the WIN-R trial. Hepatology, 38 (4 Suppl 1): 734–735A.Google Scholar
  5. Alberti, A., Clumeck, N., Collins, S., Gerlich, W., Lundgren, J.D., Palu, G., Reiss, P., Thiebaut, R., Weiland, O., Yazdanpanah, Y., Zeuzem, S. (The ECC Jury) (2005). Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV-coinfected patients. Journal of Hepatology, 42: 615–624.PubMedGoogle Scholar
  6. Algranati, N.E., Sy, S., Modi, M. (1999). A branched methoxy 40 Kda polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-INF) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology, 30: 190A; abstract 120.Google Scholar
  7. Arora, S., O’Brien, C., Zeuzem, S., Shiffman, M.L., Diago, M., Tran, A., Pockros, P.J., Reindollar, R.W., Gane, E., Patel, K., Wintfeld, N., Green, J. (2006). Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α-2a (40 Kda) plus ribavirin: Impact on health-related quality of life. Journal of Gastroenterology and Hepatology, 21: 406–412.PubMedGoogle Scholar
  8. Asahina, Y., Izumi, N., Enomoto, N., Uchihara, M., Kurosaki, M., Onuki, Y., Nishimura, Y., Ueda, K., Tsuchiya, K., Nakanishi, H., Kitamura, T., Miyake, S. (2005). Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. Journal of Hepatology, 43: 623–629.PubMedGoogle Scholar
  9. Bailon, P., Palleroni, A., Schaffer, C.A., Spence, C.L., Fung, W.J., Porter, J.E., Ehrlich, G.K., Pan, W., Xu, Z.X., Modi, M.W., Farid, A., Berthold, W., Graves, M. (2001). Rational design of a potent, long-lasting from of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugates and Chemistry, 12: 195–202.Google Scholar
  10. Balan, V., Schwartz, D., Wu, G.Y., Muir, A.J., Ghalib, R., Jackson, J., Keeffe, E.B., Rossaro, L., Burnett, A., Goon, B.L., Bowers, P.J., Leitz, G.J. (2005). Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. American Journal of Gastroenterology, 100: 299–307.PubMedGoogle Scholar
  11. Bani-Sadr, F., Carrat, F., Pol, S., Hor, R., Rosenthal, E., Goujard, C., Morand, P., Lunel-Fabiani, F., Salmon-Ceron, D., Piroth, L., Pialoux, G., Bentata, M., Cacoub, P., Perronne, C. for the ANRS Hc02-Ribavic Study Team. (2005). Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. Journal of AIDS, 40(1): 47–52.PubMedGoogle Scholar
  12. Barril, G., Quiroga, J.A., Sanz, P., Rodrìguez-Salvanés, F., Selgas, R., Carreño, V. (2004). Peglyated interferon-α2a kinetics during experimental haemodialysis: Impact of permeability and pore size of dialysers. Alimentary and Pharmacology Therapy, 20: 37–44.Google Scholar
  13. Beckebaum, S., Cicinnati, V.R., Zhang, X., Malago, M., Dirsch, O., Erim, Y., Frilling, A., Broelsch, C.E., Gerken, G. (2004). Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study. Transplant Proceedings, 36: 1489–1491.Google Scholar
  14. Benhamou, Y., Pockros, P., Rodriguez-Torres, M., Gordon, S., Shiffman, M., Lurie, Y., Afdhal, N., Lamon, K., Kim, Y., Murphy, B. (2006). The safety and efficacy of viramidine® plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy-naïve patients infected with HCV: Phase 3 results. Journal of Hepatology, 44 (Suppl 2): S273; abstract 751.Google Scholar
  15. Berenguer, M., Prieto, M., Palau, A., Carrasco, D., Rayón, J.M., Calvo, F., Berenguer, J. (2004). Recurrent hepatitis C genotype 1b following liver transplantation: Treatment with combination interferon-ribavirin therapy. European Journal of Gastroenterology and Hepatology, 16: 1207–1212.PubMedGoogle Scholar
  16. Berg, C., Goncales, F.L., Bernstein, D.E., Sette, H., Rasenack, J., Diago, M., Jensen, D.M., Graham, P., Cooksley, G. (2006a). Re-treatment of chronic hepatitis C patients after relapse: Efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. Journal of Viral Hepatology, 13: 435–440.Google Scholar
  17. Berg, T., VonWagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T., Buggisch, P., Goeser, T., Rasenack, J., Pape, G.R., Schmidt, W.E., Kallinowski, B., Klinker, H., Spengler, U., Martus, P., Alshuth, R., Zeuzem, S. (2006). Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology, 130: 1086–1097.PubMedGoogle Scholar
  18. Bernfort, L., Sennfält, K., Reichard, O. (2006). Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scandinavian Journal of Infectious Diseases, 38: 497–505.PubMedGoogle Scholar
  19. Biselli, M., Andreone, P., Gramenzi, A., Lorenzini, S., Loggi, E., Bonvicini, F., Cursaro, C., Bernardi, M. (2006). Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppresive regimen. Digest of Liver Diseases, 38: 27–32.Google Scholar
  20. Bizollon, T., Ahmed, S.N.S., Radenne, S., Chevallier, M., Chevallier, P., Parvaz, P., Guichard, S., Ducerf, C., Baulieux, J., Zoulim, F., Trepo, C. (2003). Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut, 52: 283–287.PubMedGoogle Scholar
  21. Bodenheimer, H.C., Lindsay, K.L., Davis, G.L., Lewis, J.H., Thung, S.N., Seeff, L.B. (1997). Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology, 26 : 473–477.PubMedGoogle Scholar
  22. Bonny, C., Roche, C., Fontaine, H., Poynard, T., Héxode, C., Larrey, D., Marcellin, P., Bourlière, M., Bronowicki, J.P., Merle, P., Zarski, J.P., Nicolas, C., Randl, K., Bommelaer, G., Abergel, A. (2005). Eficacy of interferon (standard or pegylated) plus ribavirin in naive patients with hepatitis C virus genotype 5. A French national study. Journal of Hepatology, 42 (Suppl 2): 200; abstract 549.Google Scholar
  23. Brau, N. (2003). Update on chronic hepatitis C in HIV/HCV-coinfected patients: Viral interactions and therapy. AIDS, 27: 2279–2290.Google Scholar
  24. Brennan, B., Morrison, R., Hagedorn, C., Marbury, T.C., Sulkowski, M., Grippo, J., Gries, J-M. (2005). Effect of ethnicity on the pharmacokinetics of ribavirin (COPEGUS®) and peginterferon alfa-2a (40KD) (PEGASYS®) in patients with chronic hepatitis C. Hepatology, 42 (Suppl 1): 653A; abstract 1161.Google Scholar
  25. Bressler, B., Wang, K., Gries, J.-M., Heathcote, J. (2005). Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha 2A (40KD) (PEGASYS®). Hepatology, 42 (Suppl 1): 661A; abstract 1183.Google Scholar
  26. Brown, R.S., Jacobson, I.M., Afdhal, N., Freilich, B., Regenstein, F., Flamm, S., Kwo, P., Pauly, M.P., Griffel, L.H., Brass, C.A. (2006). Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the Win-R trial. Gastroenterology, 130 (4 Suppl 2): A-767; abstract 523.Google Scholar
  27. Bruno, R., Sacchi, P., Maiocchi, L., Zocchetti, C., Ciappina, V., Patruno, S., Filice, G., (2005). Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Antiviral Therapy, 10: 201–205.PubMedGoogle Scholar
  28. Burton, J.R., Klarquist, J., Im, K.A., Belle, S.H., Rosen, H.R. (2006). Stronger baseline HCV-specific immunity is associated with a higher likelihood of a sustained virological response to combination antiviral therapy of chronic hepatitis C. Gastroenterology, 130 (4 Suppl 2): abstract S1057.Google Scholar
  29. Buti, M., Casado, M.A., Fosbrook, L., Esteban R. (2005). Financial impact of two different ways of evaluating early virological response to peginterferon α-2b plus ribavirin therapy in treatment-naïve patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 23: 1043–1055.PubMedGoogle Scholar
  30. Buti, M., Sanchez-Avila, F., Lurie, Y., Stalgis, C., Valdéz, A., Martell, M., Esteban, R. (2002). Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology, 35: 930–936.PubMedGoogle Scholar
  31. Byrnes, V., Miller, A., Weinstein, C., Hill, E., Lenkinski, R., Alsop, D., Afdhal, N.H. (2005). Cerebral metabolic and neuropsychiatric effects of pegylated interferon (PIFN) therapy in hepatitis C. Gastroenterology, 128 (Suppl 2): A684 [abstract].Google Scholar
  32. Cammà, C., Di Bona, D., Schepis, F., Heathcote, E.J., Zeuzem, S., Pockros, P.J., Marcellin, P., Balart, L., Alberti, A., Craxì, A. (2004). Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patients’ data. Hepatology, 39: 333–342.PubMedGoogle Scholar
  33. Carrat, F., Bani Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perronne, C. for the ANRS HCO2 RIBAVIC Study Team. (2004). Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA, 292: 2839–2848.PubMedGoogle Scholar
  34. Castera, L., Constant, A, Henry, C., Champenoit, P., Sauve, G., de Ledinghen V., Bernard P.H., Foucher, J., Demotes-Mainard, J., Couzigou, P. (2004). Psychiatric events during peginterferon and ribavirin therapy in chronic hepatitis C (CHC): Results of a prospective study in 98 patients. Journal of Hepatology, 40 (Suppl 1): 139 [abstract].Google Scholar
  35. Chalasani, N., Manzarbeitia, C., Ferenci, P., Vogel, W., Fontana, R.J., Voigt, M., Riely, C., Martin, P., Teperman, L., Jiao, J., Lopez-Talavera, J.C. for the Pegasys Transplant Study Group. (2005). Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology, 41: 289–298.PubMedGoogle Scholar
  36. Chatelut, E., Rostaing, L., Grégoire, N., Payen, J.L., Pujol, A., Izopet, J., Houin, G., Canal, P. (1999). A pharmacokinetic model for alpha interferon administered subcutaneously. British Journal of Clinical Pharmacology, 47: 365–371.PubMedGoogle Scholar
  37. Chung, R.T., Andersen, J., Volberding, P., Robbins, G.K., Liu, T., Sherman, K.E., Peters, M.G., Koziel, M.J., Bhan, A.K., Alston, B., Colquhoun, D., Nevin, T., Harb, G., van der Horst, C. for the AIDS Clinical Trials Group A5071 Study Team (2004). Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351: 451–459.PubMedGoogle Scholar
  38. ClinicalTrials.gov Identifier NCT00077649. A randomized, double-blind study of the effect of PEGASYS and ribavirin combination therapy on viral kinetics and virologic response in interferon-naïve patients with chronic hepatitis C genotype 1 infection. (Study ID number: NV17318). (http://www.clinicaltrials.gov/ct/show/NCT00077649?order=1). Accessed 9/4/06.Google Scholar
  39. ClinicalTrials.gov Identifier NCT 00255008. SEASON South East Asian study of novel genotypes in hepatitis C infection: Pegylated-interferon and ribavirin therapy (PEGATRON REDIPEN combination therapy (PEG-Intron®) REDIPEN plus REBETOL®) in treatment naïve patients with genotypes 1, 6, 7, 8, 9: A comparison of race and genotype on treatment outcome (http://www.clinicaltrials.gov/ct/show/NCT00255008?order=3). Accessed 9/4/06.Google Scholar
  40. ClinicalTrials.gov Identifier NCT00255034. Effects of 48 weeks versus 24 weeks of therapy with peg-Intron/ribavirin in patients with chronic hepatitis C, genotype 3 (study P04143) (http://www.clinicaltrials.gov/ct/show/NCT00255034). Accessed 7/29/06.Google Scholar
  41. ClinicalTrials.gov Identifier NCT00266318. Study of high dosage CIFN plus RBV for HCV genotype 1 infected patients who are nonresponders to prior therapy (http://www.clinicaltrials.gov/ct/show/NCT00266318?order=2). Accessed 8/13/06.Google Scholar
  42. ClinicalTrials.gov Identifier NCT00336479. A phase 2 study of VX-950 in combination with peginterferon-2a (Pegasys®), with ribavirin (Copegus®) in subjects with genotype 1 hepatitis C who have not received prior treatment. (Study VX05-950-104) (http://www.clinicaltrials.gov/ct/show/NCT00336479?order=1). Accessed 8/24/06.Google Scholar
  43. ClinicalTrials.gov NCT00160251. PEG-Intron/REBETOL vs PEG-Intron/SCH503034 with and without ribavirin in chronic hepatitis C HCV-1 peginterferon alfa/ribavirin nonresponders: A SCH 503034 dose-finding phase 2 study. (Study P03659AMS1) (http://www.clinicaltrials.gov/ct/show/NCT00160251?order=1). Accessed 8/30/06.Google Scholar
  44. Cohen, M.C., Huberman, M.S., Nesto, R.W. (1990). Interferon alfa-induced cardiac dysfunction. New England Journal of Medicine, 322: 1469.PubMedGoogle Scholar
  45. Collantes, R.S., Younossi, Z.M. (2005). The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. Journal of Clinical Gastroenterology, 39 (Suppl 1): S9–S13.PubMedGoogle Scholar
  46. Condat, B., Asselah, T., Zanditenas, D., Estampes, B., Cohen, A., O’Toole, D., Bonnet, J., Ngo, Y., Marcellin, P., Belazquez, M. (2006). Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 18: 287–289.PubMedGoogle Scholar
  47. Conjeevaram, H.S., Fried, M.W., Jeffers, L.J., Terrault, N.A., Wiley-Lucas, T.E., Afdhal, N., Brown, R.S., Belle, S.H., Hoofnagle, J.H., Kleiner, D.E., Howell, C.D. for the Virahep-C Study Group (2006). Peginterferon and ribavirin treatment in African Americans and Caucasian American patients with hepatitis C genotype 1. Gastroenterology, 131: 470–477.PubMedGoogle Scholar
  48. Curry, M., Cardenas, A., Afdhal, N.H. (2005). Effect of maintenance PEG-INTRON therapy on portal hypertension and its complications: Results from the COPILOT study. Journal of Hepatology, 42 (Suppl 2): 40; abstract 95.Google Scholar
  49. D’Heygere, F., George, C., Nevens, R., Van Vlierberghe, H., Van Der Meeren, O. (2005). Patients infected with HCV-5 present the same response rate as patients infected with HCV-1: Results from the Belgian randomised trial for naive and relapsers (BERNAR-1). Journal of Hepatology, 42 (Suppl 2): 203; abstract 558.Google Scholar
  50. Dalekos, G.N., Hatzis, J., Tsianos, E.V. (1998). Dermatologic disease during interferon alpha therapy for chronic viral hepatitis. Annals of Internal Medicine, 128: 409–410.PubMedGoogle Scholar
  51. Davis, G.L. (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36 (Suppl 1): S145–S151.PubMedGoogle Scholar
  52. De Franceschi, L., Fattovich, G., Turrini, F., Ayi, K., Brugnara, C, Manzato, F., Noventa, F., Stanzial, A., Solero, P., Corrocher, R. (2000). Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology, 31: 997–1004.PubMedGoogle Scholar
  53. Dereure, O., Raison-Pevron, N., Larrey, D., Blanc, F., Guilhou, J.J. (2002). Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: A series of 20 patients. British Journal of Dermatology, 147: 1142–1146.PubMedGoogle Scholar
  54. Dev, A.T., McCaw, R., Sundararajan, V., Bowden, S., Sievert, W. (2002). Southeast Asian patients with chronic hepatitis C: The impact of novel genotypes and race on treatment outcome. Hepatology, 36: 1259–1265.PubMedGoogle Scholar
  55. Diago, M.., Romero-Gomez, M.., Crespo, J., Olveira, A., Perez, R., Barcena, R., Sanchez-Tapias, J.M., Munoz-Sanchez, M. (2006). Pharmacokinetics and pharmacodynamics of induction doses of peginterferon alpha-2a (40 KD) (PEGASYS®) and ribavirin (COPEGUS®) in HCV genotype 1 patients who failed to respond to interferon/ribavirin. Journal of Hepatology, 44 (Suppl 2): S210; abstract 566.Google Scholar
  56. DiBisceglie, A.M., Fan, X., Chambers, T., Strinko, J. (2006). Pharmacokinetics, pharmacodynamics and hepatitis C viral kinetics during antiviral therapy: The null responder. Journal of Medical Virology, 78: 446–451.Google Scholar
  57. Dieterich, D., Lawitz, E., Nguyen, T., Younes, Z., Santoro, J., Gitlin, N., McEniry, D., Chasen, R., Goff, J., Knox, S., Kleber, K., Belanger, B., Brown, N. (2006). Early clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naive patients with HCV-1 infection: First results form a phase IIb trial. Journal of Hepatology, 44 (Suppl 2): S271; abstract 736.Google Scholar
  58. Dominguez, S., Ghosn, J., Valantin, M.A., Schruniger, A., Simon, A., Bonnard, P., Caumes, E., Pialoux, G., Benhamou, Y., Thibault, V., Katlama, C. (2006). Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS, 20: 1157–1161.PubMedGoogle Scholar
  59. Dumortier, J., Scoazec, J., Chevallier, P., Boillot, O. (2004). Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. Journal of Hepatology, 40: 669–674.PubMedGoogle Scholar
  60. Dusheiko, G., Main, J., Thomas, H., Reichard, O., Lee, C., Dhillon, A., Rassam, S., Fryden, A., Reesink, H., Bassendine, M., Norkrans, G., Cuypers, T., Lelie, N., Tefler, P., Watson, J., Weegink, C., Sillikens, P., Weiland, O. (1996). Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. Journal of Hepatology, 25: 591–598.PubMedGoogle Scholar
  61. Elefsiniotis, I.S., Pantazis, K.D., Fotos, N.V., Moulakakis, A., Mavrogiannis, C. (2006). Late onset autoimmune thrombocytopenia associated with pegylated interferon alfa-2b plus ribavirin treatment for chronic hepatitis C. Journal of Gastroenterology and Hepatology, 21: 622–623.PubMedGoogle Scholar
  62. Elmakhzangy, H., Rekacewicz, C., Shouman, S.I., Mohamed, H.N., Esmat, G., Ismail, A., Rafaat, R., El Hosseiny, M., El Daly, M., El Kafrawy, S., Abdel Hamid, M., Fontanet, A., Pol, S., Mohamed, M.K. (2005). Combined pegylated interferon alfa-2a and ribavirin treatment of chronic hepatitis C in Egypt (ANRS 1211 Trial). Journal of Hepatology, 42 (Suppl 2): 203; abstract 559.Google Scholar
  63. Farel, C., Suzman, D.L., McLaughlin, M. (2004). Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peg interferon alpha-2b and ribavirin. AIDS, 18: 1805–1809.PubMedGoogle Scholar
  64. Ferenci, P., Bergholz, U., Laferl, H., Scherzer, T.M., Maieron, A., Gschwantler, M., Brunner, H., Hubmann, R.R., Datz, C., Bischof, M., Stauber, R., Steindl-Munda, P. (2006). 24 week treatment regimen with peginterrferon alpha-2a (40 KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 “super-responders.” Journal of Hepatology, 44 (Suppl 2): S6; abstract 8.Google Scholar
  65. Ferenci, P., Fried, M.W., Shiffman, M.L., Smith, C.I., Marinos, G., Gonçales, F.L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxì, A., Chaneac, M., Reddy, K.R. (2005). Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. Journal of Hepatology, 43: 425–433.PubMedGoogle Scholar
  66. Firpi, R., Abdelmalek, M., Soldevila-Pico, C. (2002). Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplantation, 8: 1000–1006.PubMedGoogle Scholar
  67. Fonseca, V., Thomas, M., Dusheiko, G. (1991). Thyrotropin receptor antibodies following treatment with recombinant alpha-interferon in patients with hepatitis. Acta Endocrinology, 125 : 491–493.Google Scholar
  68. Food and Drug Administration Antiviral Drugs Committee Briefing document. Pegylated interferon alfa 2a (Pegasys®). Bethesda, MD (May 16, 2006). http://www.fda.gov/ohrms/dockets/ac/02/briefing/3909b1.htm.Google Scholar
  69. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gonçales, F.L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347: 975–982.PubMedGoogle Scholar
  70. Fried, M.W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36 (5 Suppl 1): S237–S244.PubMedGoogle Scholar
  71. Gaglio, P., Choi, J., Zimmerman, D., Heller, L., Brown R.S. (2005). Weight based ribavirin in combination with pegylated interferon alpha 2-B does not improve SVR in HCV infected patients who failed prior therapy: Results in 454 patients. Hepatology, 42 (4 Suppl 1): 219A; abstract 59.Google Scholar
  72. Gane, E., Diago, M., Mohankumar, A., Wintfeld, N., Patel, K., Zeuzem, S., Shiffman, M., Reindollar, R. (2005). Health-related quality of live (HRQL) in chronic hepatitis C (CHC) patients with elevated vs. persistently “normal” ALT levels (PNALT): Comparison of data from patients treated with peginterferon alfa-2a (40 KD) plus ribavirin in two multinational trials. Gastroenterology 128 (4 Suppl 2): A-747; abstract M956.Google Scholar
  73. Ganser, A., Carlo-Stella, C., Greher, J., Volkers, B., Hoelzer, D. (1987). Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood, 70: 1173–1179.PubMedGoogle Scholar
  74. Garfein, R.S., Doherty, M.C., Monterroso, E.R., Thomas, D.L., Nelson, K.E., Vlahov, D. (1998). Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. Journal of AIDS Human Retrovirology, 18 (Suppl 1): S11–S19.Google Scholar
  75. Ghosn, J., Pierre-François, S., Thibault, V., Duvivier, C., Tubiana, R., Simon, A., Valantin, M.A., Dominguez, S., Caumes, E., Katlama, C. (2004). Acute hepatitis C in HIV-infected men who have sex with men. HIV Medicine, 5: 303–306.PubMedGoogle Scholar
  76. Giostra, E., Kullak-Ublick, G., Keller, W. (2004). Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transplantation International, 17: 169–176.Google Scholar
  77. Glue, P., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S.K., Salfi, M., Jacobs, S., Clement, R.P., the Hepatitis C Intervention Therapy Group. (2000a). A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology, 32: 647–653.Google Scholar
  78. Glue, P., Fang, J.W.S., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S.K., Salfi, M., Jacobs, S., the Hepatitis C Intervention Therapy Group. (2000b). Pegylated interferon α-2b: Pharmacokinetics, pharmacodynamkics, safety, and preliminary efficacy data. Clinical Pharmacology Therapy, 68: 556–567.Google Scholar
  79. González-Peralta, R.P., Kelly, D.A., Harber, B., Molleston, J., Murray, K.F., Jonas, M.M., Shelton, M., Mieli-Verganti, G., Lurie, Y., Martin, S., Lang, T., Baczkowski, A., Geffner, M., Gupta, S., Laughlin, M., for the International Pediatric Hepatitis C Therapy Group. (2005). Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics. Hepatology, 42: 1010–1018.PubMedGoogle Scholar
  80. Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J.-C., Hirschel, B., Janin, P., Francioli, P., Flepp, M., Telenti, A. for the Swiss HIV Cohort Study (2000). Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co infection: The Swiss HIV Cohort Study. Lancet, 356: 1800–1805.PubMedGoogle Scholar
  81. Gross, J., Johnson, S., Kwo, P., Afdhal, N., Flamm, S., Therneau, T.M. (2005). Double-dose peginterferon alfa-2b with weight based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: Final results of “RENEW.” Hepatology, 42 (4 Suppl 1): 219A–220A; abstract 60.Google Scholar
  82. Gross, J., Johnson, S.M., Therneau, T.M., Kwo, P.Y. (2005a). Double-dose peginterferon alfa-2b plus weight-based ribavirin for re-treatment of African-American non-responders with hepatitis C. Gastroenterology, 128 (4 Suppl 2): A-684; abstract 87.Google Scholar
  83. Gupta, S.K., Glue, P., Jacobs, S., Belle, D., Affrime, M. (2003). Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha 2b in young and elderly healthy subjects. British Journal of Clinical Pharmacology, 56: 131–134.PubMedGoogle Scholar
  84. Gupta, S.K., Pittenger, A.L., Swan, S.K., Marbury, T.C., Tobillo, E., Batra, V., Sack, M., Glue, P., Jacobs, S., Affrime, M. (2002). Single-dose pharmacokinetics and safety of pegylated interferon-α2b in patients with chronic renal dysfunction. Journal of Clinical Pharmacology, 42: 1109–1115.PubMedGoogle Scholar
  85. Gurguta, C., Kauer, C., Bergholz, U., Formann, E., Steindl-Munda, P., Ferenci, P. (2006). Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark skinned non-Caucasian patients with chronic hepatitis C. American Journal of Gastroenterology, 101: 197–198.PubMedGoogle Scholar
  86. Hadziyannis, S.J., Sette, H., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M. PEGASYS International Study Group. (2004). Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.PubMedGoogle Scholar
  87. Harris, J.M., Martin, N.E., Modi, M. (2001). Pegylation: A novel process for modifying pharmacokinetics. Clinical Pharmacokinetics, 40: 539–551.PubMedGoogle Scholar
  88. Hasan, F., Alsarraf, K., Qabandi, W. (2006). Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents: A pilot study. Gastroenterology, 130 (Suppl 2): A-840; abstract T1819.Google Scholar
  89. Hasan, F., Asker, H., Al-Khalid, J., Siddique, I., Al-Ajmi, M., Owaid, S., Varghese, R., Al-Nakib, B. (2004). Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. American Journal of Gastroenterology, 99: 1733–1737.PubMedGoogle Scholar
  90. Hassanein, T., Cooksley, G., Sulkowski, M., Smith, C., Marinos, G., Lai, M-Y., Pastore, G., Trejo-Estrada, R., Vale, A.H.E., Wintfeld, N., Green, J. (2004). The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology, 40: 675–681.PubMedGoogle Scholar
  91. Heathcote, E.J., Pockros, P.J., Fried, M.E., Bain, M.A., DePamphilis, J., Modi, M. (1999). The pharmacokinetics of pegylated-40K interferon alfa-2a (PEG-IFN) in chronic hepatitis C (CHC) patients with cirrhosis. Gastroenterology, 116: A735; abstract G3190.Google Scholar
  92. Heathcote, E.J., Shiffman, M.L., Cooksley, W.G.E., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., DePamphilis, J. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine, 343: 1673–1680.PubMedGoogle Scholar
  93. Herrine, S.K., Brown, R.S., Bernstein, D.E., Ondovik, M.S., Lentz, E., Te, H. (2005). Peginterferon α-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon α-2b plus ribavirin: A pilot study of efficacy and safety. Digestive Disease Sciences, 50: 719–726.Google Scholar
  94. Herrmann, E., Lee, J.-H., Marinos, G., Modi, M., Zeuzem, S. (2003). Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology, 37: 1351–1358.PubMedGoogle Scholar
  95. Hershow, R.C., O’Driscoll, P.T., Handelsman, E., Pitt, J., Hillyer, G., Serchuck, L., Lu, M., Chen, K.T., Yawetz, S., Pacheco, S., Davenny, K., Adeniyi-Jones, S., Thomas, D.L. (2005). Hepatitis C virus coinfection and HIV load, CD4 + cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and infants transmission study. Clinical Infectious Diseases, 40: 859–867.PubMedGoogle Scholar
  96. Homoncik, M., Jessner, W., Sieghardt, W. (2003). Effect of therapy with interferon-alpha and pegylated interferon-alpha on platelet plug formation in patients with chronic hepatitis C. Journal of Hepatology, 38 (Suppl 2): 145; abstract 497.Google Scholar
  97. Hornberger, J., Dusheiko, G., Lewis, G., Patel, K. (2005). An evaluation of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for the first treatment of mild chronic hepatitis C (CHC). Hepatology, 42 (4 Suppl 1): 653A; abstract 1162.Google Scholar
  98. Howell, C., Dowling, T., Haritos, M., Terrault, N., Thelma, W.-L., Taylor, M. (2006). Relationship between serum peginterferon and 2,5-OAS kinetics and virologic responses in African Americans and Caucasians patients with chronic hepatitis C, genotype 1, during peginterferon combination therapy. Gastroenterology, 130 (4 Suppl 2): abstract 199.Google Scholar
  99. Hui, C.K., Yuen, M.F., Sablon, E., Chan, A.O., Wong, B.C., Lai, C.L. (2003). Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: A comparison with genotype 1. Journal of Infectious Diseases, 187: 1071–1074.PubMedGoogle Scholar
  100. Hultgren, C., Milich, D.R., Weiland, O., Sällberg, M. (1998). The antiviral compound ribavirin modulates the T helper (Th) 1/Th 2 subset balance in hepatitis B and C virus-specific immune responses. Journal of General Virology, 79: 2381–2391.PubMedGoogle Scholar
  101. Hurst, E.A., Mauro, T. (2005). Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C. Archives of Dermatology, 141: 865–868.PubMedGoogle Scholar
  102. Imagawa, A., Itoh, N., Hanafusa, T., Oda, Y., Waguri, M., Miyagawa, J. (1995). Autoimmune endocrine disease induced by recombinant interferon-α therapy for chronic active type C hepatitis. Endocrinology and Metabolism, 80: 922–926.Google Scholar
  103. Izumi, N., Iino, S., Okuno, T., Omata, M., Kiyosawa, K., Kumada, H., Hayashi, N., Yamada, G., Sakai, T. (2006). High response rates with peginterferon α-2a (40KD) (PEGASYS®) PLUS ribavirin (Copegus®) in Japanese non-responders or relapsers to conventional interferon. Journal of Hepatology, 44 (Suppl 2): S216; abstract 582.Google Scholar
  104. Jacobson, I., Brown, R., McCone, J., Black, M., Albert, C., Dragutsky, M., Siddiqui, F., Hargrave, T., Kwo, P., Gitlin, N.l, Lambiasi, L., Galler, G., Araya, V., Freilich, B., Harvey, J., Bass, C., and the WIN-R Study Group. (2004). Weight-based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-American (AA) compared to flat dose ribavirin with peginterferon alfa-2b combination therapy. Hepatology 40 (4 Suppl 1): 217A; abstract 125.Google Scholar
  105. Jacobson, I.M., Brown, R.S., Freilich, B., Afdhal, N., Kwo, P., Santoro, J., Becker, S., Wakil, A., Pound, D., Godofsky, E., Straus, R., Bernstein, D., Flamm, S., Bala, N., Araya, V., Davis, M., Monsour, H., Vierling, J., Regenstein, F., Balan, V., Dragutsky, M., Epstein, M., Herring, R.W., Rubin, R., Galler, G., Pauly, M.P., Griffel, L.H., Brass, C.A., The WIN-R Study Group. (2005). Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, a US community based trial. Hepatology, 42 (Suppl 1): 749A; abstract LB03.Google Scholar
  106. Jacobson, I.M., Brown, R.S., Freilich, B., Afdhal, N., Kwo, P., Santoro, J., Becker, S., Wakil, A., Pound, D., Ahmed, F., Griffel, L.H., Brass, C.A. (2006). Stratification of high viral load: Impact on sustained virologic response in the Win-R trial. Gastroenterology, 130 (4 Suppl 2): A837; abstract T1806.Google Scholar
  107. Jacobson, I.M., Gonzalez, S.A., Ahmed, F., Lebovics, E., Min, A.D., Bodenheimer, H.C., Esposito, S.P., Brown, R.S., Bräu, N., Klion, F.M., Tobias, H., Bini, E.J., Brodsky, N., Cerulli, M.A., Aytaman, A., Gardner, P.W., Beders, J.M., Spivack, J.E., Rahmin, M.G., Berman, D.H., Ehrlich, J., Russo, M.W., Chait, M., Rovner, D., Edlin, B.R. (2005). A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C. American Journal of Gastroenterology, 100: 2453–2462.PubMedGoogle Scholar
  108. Jeffers, L.J., Cassidy, W., Howell, C.D., Hu, S., Reddy, K.R. (2004). Peginterferon alfa-2a (40kd) and ribavirin for Black American patients with chronic HCV genotype 1. Hepatology, 39: 1702–1708.PubMedGoogle Scholar
  109. Jensen, D.M., Morgan, T.R., Marcellin, P., Pockros, P.J., Reddy, K.R., Hadziyannis, S.J., Ferenci, P., Ackrill, A.M., Willems, B. (2006). Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology, 43: 954–960.PubMedGoogle Scholar
  110. Jessner, W., Kinaciyan, T., Formann, E. (2002). Severe skin reactions during therapy for chronic hepatitis C associated with delayed hypersensitivity to pegylated interferons. Hepatology, 36: 361A; abstract 793.Google Scholar
  111. Kaiser, S., Hass, H., Lutze, B., Gregor, M. (2006). Comparison of daily Consensus interferon versus peginterferon alfa-2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients. Gastroenterology, 130: A-784; abstract S1060.Google Scholar
  112. Kamal, S.M., El Tawil, A.A., Nakano, T., He, Q., Rasenack, J., Hakam, S.A., Saleh, W.A., Ismail, A., Aziz, A.A., Ali Madwar, M. (2005). Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut, 54: 858–866.PubMedGoogle Scholar
  113. Kamal, S.M., Fehr, J., Roesler, B., Peters, T., Rasenack, J.W. (2002). Peginterferon alone or with ribavirin enhances HCV-specific CD4+ T-Helper 1 responses in patients with chronic hepatitis C. Gastroenterology, 123: 1070–1083.PubMedGoogle Scholar
  114. Kamal, S.M., Fouly, A.E., Kamel, R.R., Hockenjos, B., Al Tawil, A., Khalifa, K.E., He, Q., Koziel, M.J., El Naggar, K.M., Rasenack, J., Afdhal, N.H. (2006a). Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterology, 130: 632–638.Google Scholar
  115. Kamal, S.M., Moustafa, K.N., Chen, J., Fehr, J., Moneim, A.A., Khalifa, K.E., El Gohary, L.A., Ramy, A.H., Madwar, M.A., Rasenack, J., Afdhal, N.H. (2006b). Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology, 43: 923–931.Google Scholar
  116. Ketikoglou, I., Karatapanis, S., Elefsiniotis, I., Kafiri, G., Moulakakis, A. (2005), Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. European Journal of Dermatology, 15: 107–109.PubMedGoogle Scholar
  117. Khuroo, M.S., Khuroo, M.S., Dahab, S.T. (2004). Meta-analysis: A randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Alimentary Pharmacology and Therapy, 20: 931–938.Google Scholar
  118. Kozlowski, A., Harris J.M. (2001). Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C. Journal of Controlled Release, 72: 217–224.PubMedGoogle Scholar
  119. Kramer, J.R., Giordano, T.P., Souchek, J., El-Serag, H.B. (2005). Hepatitis C co infection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. Journal of Hepatology, 42: 309–314.PubMedGoogle Scholar
  120. Kraus, M.R., Schäfer, A., Faller, H., Csef, H., Scheurlen, M. (2002). Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Alimentary Pharmacology and Therapy, 16: 1091–1099.Google Scholar
  121. Kraus, M.R., Schafer, A., Wibmann, S., Reimer, P., Scheurlen, M. (2005). Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clinical Pharmacology and Therapy, 77 : 90–100.Google Scholar
  122. Kuehne, F., Bethe, U., Freedberg, K., Goldie, S. (2002). Treatment for hepatitis C virus in HIV-infected patients: Clinical benefits and cost-effectiveness. Archives of Internal Medicine, 162: 2545–2556.PubMedGoogle Scholar
  123. Kuo, A., Terrault, N.A. (2006). Management of hepatitis C in liver transplant recipients. American Journal of Transplantation, 6: 449–458.PubMedGoogle Scholar
  124. Kuwata, A., Ohashi, M., Sugiyama, M., Ueda, R., Dohi, Y. (2002). A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma. American Journal of Medicine, 324: 331–334.Google Scholar
  125. Lam, N.P., Pitrak, D., Speralakis, R., Lau, A.H., Wiley, T.E., Layde, T.J. (1997). Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Digestive Disease Sciences, 42: 178–185.Google Scholar
  126. Lamb, M.W., Martin, N.E. (2002). Weight-based versus fixed dosing of peginterferon (40 kDa) alfa-2a. Annals of Pharmacotherapy, 36: 933–935.PubMedGoogle Scholar
  127. Lamb, M.W., Marks, I.M., Wynohradnyk, L., Modi, M.W., Preston, R.A., Pappas, C. (2001). 40 KDA peginterferon alfa-2a (PEGASYS®) can be administered safely in patients with end-stage renal disease. Hepatology, 34: 326A; abstract 618.Google Scholar
  128. Lauer, G.M., Walker, B.D. (2001). Hepatitis C virus infection. New England Journal of Medicine, 345: 41–52.PubMedGoogle Scholar
  129. Lebray, P., Nalpas, B., Vallet-Picard, A., Broissand, C., Sobesky, R., Serpaggi, J., Fontaine, H., Pol, S. (2005). The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antiviral Therapy, 10: 769–776.PubMedGoogle Scholar
  130. Lee, S.S., Heathcote, E.J., Reddy, K.R., Zeuzem, S., Fried, M.W., Wright, T.L., Pockros, P.J., Häussinger, D., Smith, C.I., Lin, A., Pappas, S.C. (2002). Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). Journal of Hepatology, 37: 500–506.PubMedGoogle Scholar
  131. Lee, W., Dieterich, D. (2004). Challenges in the management of HIV and hepatitis C virus co-infection. Drugs, 64: 693–700.PubMedGoogle Scholar
  132. Lin, K., Perni, R.B., Kwong, A.D., Lin, C. (2006). VX-950, a novel hepatitis C (HCV) NS3-4a protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrobial Agents and Chemotherapy, 50: 1813–1822.PubMedGoogle Scholar
  133. Lindsay, K.L., Trepo, C., Heintges, T., Schiffman, M.L., Gordon, S.C., Hoefs, J.C., Schiff, E.R., Goodman, Z.D., Laughlin, M., Yao, R., Albrecht, J.K., for the Hepatitis Interventional Therapy Group. (2001). A randomized, double blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology, 34: 395–403.PubMedGoogle Scholar
  134. Lisker-Melman, M., Di Bisceglie, A.M., Usala, S.J., Weintraub, B., Murray, L.M., Hoofnagle, J.H. (1992). Development of thyroid disease during therapy of viral hepatitis with interferon alfa. Gastroenterology, 102: 2155–2160.PubMedGoogle Scholar
  135. Lutchman, G., Hoofnagle, J.H. (2003). Viral kinetics in hepatitis C. Hepatology, 37: 1257–1259.PubMedGoogle Scholar
  136. Luxon, B.A., Grace, M., Brassard, D., Bordens, R. (2002). Pegylated interferons for the treatment of chronic hepatitis C infection. Clinical Therapy, 24: 1363–1383.Google Scholar
  137. Macias, J., Castellano, V., Merchante, N., Palacios, R.B., Mira, J.A., Saez, C., Garcia-Garcia, J.A., Lozano, F., Gomez-Mateos, J.M., Pineda, J.A. (2004). Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine. AIDS, 18: 767–774..PubMedGoogle Scholar
  138. Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A. (2005). Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 353: 2609–2617.Google Scholar
  139. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet, 358: 958–965.PubMedGoogle Scholar
  140. Marcellin, P., Jensen, D. (2005). Retreatment with PEGASYS® in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy-efficacy analysis of the 12-week induction period of the REPEAT study. Hepatology, 42 (4 Suppl 1): 749A; abstract LB04.Google Scholar
  141. Martin, N.E., Modi, M.W., Reddy, R. (2000a). Characterization of pegylated (40KDA) interferon alfa-2a (PEGASYS) in the elderly. Hepatology, 32: 348A; abstract 755.Google Scholar
  142. Martin, P., Mitra, S., Farrington, K., Martin, N.E., Modi, M.W. (2000b). Pegylated (40 KDA) alfa-2a (PEGASYS) is unaffected by renal impairment. Hepatology, 32: 370A; abstract 842.Google Scholar
  143. Mauss, S., Berger, F., Goelz, J., Jacob, B., Schmutz, G. (2004a). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40: 120–124.Google Scholar
  144. Mauss, S., Valenti, W., DePamphilis, J. (2004b). Risk factors for hepatic decompensation in patients with HIV/HCV co infection and liver cirrhosis during interferon-based therapy. AIDS, 18: 21–25.Google Scholar
  145. McHutchison, J.G., Ghalib, R., Lawitz, E., Kwo, P., Freilich, B., Muir, A., Masciari, F., Morris, M.L., Himes, J.L., Al-Adhami, M., Bacon, B.R. (2006). Early viral response to CPG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. Journal of Hepatology, 44 (Suppl 2): S269; abstract 730.Google Scholar
  146. Meier, V., Bürger, E., Mihm, S., Saile, B., Ramadori, G. (2003). Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: Possible explanation for therapeutic efficacy in patients with chronic HCV infection. Journal of Medical Virology, 69: 50–58.PubMedGoogle Scholar
  147. Modi, M.W., Fried, M., Reindollar, R.W., Rustgi, V.R., Kenny, R., Wright, T.L., Gibas, A., Martin, N.E. (2000a). The pharmacokinetic behavior of pegylated (40KDA) interferon alfa-2a (PEGASYS) in chronic hepatitis C patients after multiple dosing. Hepatology, 32: 394A; abstract 939.Google Scholar
  148. Modi, M.W., Fulton, J.S., Buckmann, D.K., Wright, T.L., Moore, D.J. (2000b). Clearance of pegylated (40 KDA) interferon alfa-2a (PEGASYSTM) is primarily hepatic. Hepatology, 32: 371A; abstract 848.Google Scholar
  149. Moore, M.M., Elpern, D.J., Carter, D.J. (2004). Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Archives in Dermatology, 140: 215–217.Google Scholar
  150. Mukherjee, S., Lyden, E., McCashland, T.M., Schafer, D.F. (2005). Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: Cohort study of 38 patients. Journal of Gastroenterology and Hepatology, 20: 198–203.PubMedGoogle Scholar
  151. Mukherjee S., Rogge J., Weaver L., and Schafer D.F. (2003). Pilot study of pegylated interferon Alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proceedings, 35: 3042–3044.Google Scholar
  152. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. (2002). Hepatology, 36 (Suppl 1): S3–S20.Google Scholar
  153. Neff, G.W., Montalbano, M., O’Brien, C.B., Nishida, S., Safdar, K., Bejarano, P.A., Khaled, A.S., Ruiz, P., Slapak-Green, G., Lee, M., Nery, J., De Medina, M., Tzakis, A., Schiff, E.R. (2004). Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation, 78: 1303–1307.PubMedGoogle Scholar
  154. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T. E., Layden, T.J., Perelson, A.S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282: 103–107.PubMedGoogle Scholar
  155. Neumann, A.U., Zeuzem, S., Ferrari, C., Lurie, Y., Negro, F., Germanidis, G., Esteban, J., Hellstrand, K., Pellegrin, B., Soulier, A., Haagmans, B., Abrignani, S., Colucci, G., Schalm, S.W., Pawlotsky, J.-M.. (2002). DITTO-HCV early viral kinetics report novel decline patterns in Gen 1 but not Gen 2-3 patients treated with PEG-interferon-alfa-2a and ribavirin. Journal of Hepatology, 36 (Suppl 1): 121; abstract 430.Google Scholar
  156. Nevens, F., Van Vlierberghe, H., D’Heygere, F., Delwaide, J., Adler, M., Henrion, J., Henry, J.P., Hendlisz, A., Michielsen, P., Bastens, B., Brenard, R., Van Der Meeren, O. (2005). Peginterferon α-2a (40 kDa) plus ribavirin is as effective in patients relapsing after conventional interferon based therapy as in naïve patients: Results from the Bernar-1 trial. Journal of Hepatology, 42 (Suppl 2): 214; abstract 588.Google Scholar
  157. Nguyen, M.D., Trinh, H.N., Garcia, R.T., Ning, J., Keeffe, B. (2003). Evaluation and outcomes of combination therapy with interferon or peginterferon plus ribavirin in 67 Southeast Asian patients with hepatitis C genotype 6, 7, 8, and 9. Hepatology, 38 (4 Suppl 1): 645A; abstract 1014.Google Scholar
  158. Nunez, M., Benito, J.M., Lopez, M. (2003). Hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September [abstract H-1717].Google Scholar
  159. Oton, E., Barcena, R., Garcia-Garzon, S., Moreno-Zamora, A., Moreno, A., Garcia-Gonzalez, M., Blesa, C., Foruny, J.R., Ruiz, P. (2005). Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant Proceedings, 37: 3963–3964.Google Scholar
  160. Pawlotsky, J.-M., Dahari, H., Neumann, A.U., Hezode, C., Germanidis, G., Lonjon, I., Castera, L., Dhumeaux, D. (2004). Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology, 126: 703–714.PubMedGoogle Scholar
  161. Pawlotsky, J.-M., Hezode, C., Pellegrin, B., Soulier, A., won Wagner, M., Brouwer, J.T., Missale, G., Germanidis, G., Lurie, Y., Negro, F., Esteban, J., Hellstrand, K., Ferrari,C., Zeuzem, S., Schalm, S.W., Neumann, A. (2002). Early HCV genotype 4 replication kinetics during treatment with peginterferon alfa-2a (PEGASYS)-ribavirin combination. A comparison with HCV genotypes 1 and 3 kinetics. Hepatology, 36: 291A; abstract 511.Google Scholar
  162. Peginterferon alfa-2a, Pegasys [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2004.Google Scholar
  163. PEG-INTRON(R) Powder for Injection, peginterferon alfa-2b [package insert]. Kenilworth, NJ, Schering Corporation; 2005.Google Scholar
  164. Planas, J.M., Gonzalez, E.R., Grana, E.B., Botella, A.G., Peinado, C.B., Poza, J.L., Garrido, M.J., Turrion, V.S., Martinez, V.C. (2005). Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proceedings, 37 : 2207–2208.Google Scholar
  165. Pockros, P., O’Brien, C., Godofsky, E., Rodriguez-Torres, M., Afdhal, N., Pappas, S.C., Lawitz, E., Bzowej, N., Rustgi, V., Sulkowski, M., Sherman, K., Jacobson, I., Chao, G., Knox, S., Pietropaolo, K., Brown, N. (2006). Valopicitabine (NM283), alone or with PEG-interferon, compared to PEG interferon/ribavirin (pegIFN/RBV) retreatment in hepatitis C patients with prior non-response to pegIFN/RBV: Week 24 results. Gastroenterology, 130 (4 Suppl 2): A-748; abstract 4.Google Scholar
  166. Pockros, P.J., Carithers, R., Desmond, P., Dhumeaux, D., Fried, M.W., Marcellin, P., Shiffman, M.L., Minuk, G., Reddy, K.R., Reindollar, R.W., Lin, A., Brunda, M.J., for the PEGASYS® International Study Group. (2004). Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: A multicenter, randomized controlled trial. American Journal of Gastroenterology, 99: 1298–1305.PubMedGoogle Scholar
  167. Poynard, T., Schiff, E., Terg, R., Goncales, F., Flamm, S., Diago, M., Reichen, J., Moreno, R., Tanno, H., McHutchison, J., Fainboim, H., Berg, T., Mattos, A., Burak, K., Mukhopadhyay, P., Bedossa, P., Griffel, L., Burroughs, M., Brass, C., Albrecht, J. (2005). Sustained virologic response (SVR) with PEG-Interferon-alfa 2b/ribavirin weight based dosing in previous interferon/ribavirin HCV treatment failures; week 12 virology as a predictor of SVR in the EPIC3 trials. Gastroenterology, 128 (Suppl 2): A681; abstract 5.Google Scholar
  168. Preziati, D., La Rosa, L., Covini, G., Marcelli, R., Rescalli, S., Persani, L. (1995). Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. European Journal of Endocrinology, 132: 587–593.PubMedGoogle Scholar
  169. Ramos, B., Nunez, M., Rendon, A. (2006). High ribavirin doses and early virological response in HCV/HIV-coinfected patients. Program and abstracts of the 2nd International Workshop on HIV and Viral Hepatitis Co infection; January 12-14, Amsterdam, The Netherlands. Abstract 36.Google Scholar
  170. Rasenack, J., Zeuzem, S., Feinman, V., Heathcote, E.J., Manns, M., Yoshida, E.M., Swain, M.G., Gane, E., Diago, M., Revicki, D.A., Lin, A., Wintfeld, N., Green, J. (2003). Peginterferon α-2a (40 kD) [PEGASYS®] improves HR-QOL outcomes compared with unmodified interferon α-2a [Roferon®-A] in patients with chronic hepatitis C. Pharmacoeconomics, 21: 341–349.PubMedGoogle Scholar
  171. Rauch, A., Rickenbach, M., Weber, R. (2005). Association of unsafe sex and increased incidence of hepatitis C infection in HIV-infected men who have sex with men. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, Boston, MA. Abstract 943.Google Scholar
  172. Reddy, K.R., Wright, T.L., Pockros, P.J., Shiffman, M., Everson, G., Reindollar, R., Fried, M.W., Purdum, P.P., Jensen, D., Smith, C., Lee, W.M., Boyer, T.D., Lin, A., Pedder, S., DePamphilis, J. (2001). Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology, 33: 433–438.PubMedGoogle Scholar
  173. Reesink, H.W., Zeuzem, S., Weegink, C.J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L.A., Purdy, S., Chu H-M., Jansen, P.L. (2005). Final results of a Phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Hepatology 42 (4 Suppl 1): 234A; abstract 96.Google Scholar
  174. Rendon, A.L., Nunez, M., Romero, M., Barreiro, P., Martin-Carbonero, L., Garcia-Samaniego, J., Jimenez-Nacher, I., Gonzalez-Lahoz, J., Soriano V. (2005). Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients. Journal of AIDS, 39: 401–405.PubMedGoogle Scholar
  175. Rhodes, S., Erlich, H., Im, K.A., Wang, J., Li J., Bugawan, T., Jeffers, L., Tong, X., Su, X., Lee, L.J., Liang, T.J., Yang, H. (2006). Association between HLA allele a*02, B*58, Dpb*1701 and sustained virologic response to pegylated interferon and ribavirin therapy in chronic HCV genotype 1-infected, treatment naïve Caucasian and African Americans. Gastroenterology, 130 (4 Suppl 2): A-771; abstract 656.Google Scholar
  176. Sakai, T., Iino, S., Okuno, T., Omata, M., Kiyosawa, K., Kumada, H., Yamada, G., Hayashi, N. (2006). High response rates with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naïve Japanese chronic hepatitis C patients: A randomized, double-blind, multicentre, phase III trial. Journal of Hepatology, 44 (Suppl 2): S224; abstract 605.Google Scholar
  177. Sánchez-Tapias, J.M., Diago, M., Escartín, P., Enríquez, J., Romero-Gómez, M., Bárcena, R., Crespo, J., Andrade, R., Martínez-Bauer, E., Pérez, R., Testillano, M., Planas, R., Solá, R., García-Bengoechea, M., Garcia-Samaniego, J., Munoz-Sánchez, M., Moreno-Otero, R.; TeraViC-4 Study Group. (2006). Peginterferon-alfa 2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology, 131: 451–460.PubMedGoogle Scholar
  178. Schmid, M., Kreil, A., Jessner, W., Homoncik, M., Datz, C., Gangl, A., Ferenci, P., Peck-Radosavljevic, M. (2005). Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon α mono and combination therapy regimens. Gut, 54: 1014–1020.PubMedGoogle Scholar
  179. Schulman, J.A., Liang, C., Kooragayala, L.M., King, J. (2003). Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology, 110: 437–442.PubMedGoogle Scholar
  180. Schwaiger, M., Pich, M., Granke, L. (2003). Chronic hepatitis C infection, interferon alpha treatment and peripheral serotonergic dysfunction. Hepatology, 38 (Suppl 1): 300A; abstract 301.Google Scholar
  181. Schwarz, K., Mohan, P., Narkewicz, M., Molleston, J.P., Te, H.S., Hu, S., Sheridan, S., Lamb, M., Pappas, S.C., Harb, G. (2003). The safety, efficacy and pharmacokinetics of peginterferon alfa-2a (40KD) in children with chronic hepatitis C. Gastroenterology, 124 (Suppl 1): A-700; abstract 215.Google Scholar
  182. Seeff, L. (2002). Natural history of chronic hepatitis C. Hepatology, 36 (Suppl 1): S35–S46.PubMedGoogle Scholar
  183. Sheiner, P.A., Boros, P., Klion, F.M., Thung, S.N., Schluger, L.K., Lau, J.Y., Mor, E., Bodian, C., Guy, S.R., Schwartz, M.E., Emre, S., Bodenheer, H.C., Miller, C.M. (1998). The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology, 28: 831–838.PubMedGoogle Scholar
  184. Shen, Y., Pielop, J., Hsu, S. (2005). Generalized nummular eczema secondary to peg interferon alfa-2b and ribavirin combination therapy for hepatitis C infection. Archives of Dermatology, 141: 102–103.PubMedGoogle Scholar
  185. Shepherd, J., Brodin, H., Cave, C., Waugh, N., Price, A., Gabbay, J. (2004). Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technology Assessment, 8: 1–125.Google Scholar
  186. Shergill, A., Khalili, M., Bollinger, K., Roberts, J., Ascher, N., Terrault, N. (2005). Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C infected patients undergoing liver transplantation. American Journal of Transplantation, 5: 118–124.PubMedGoogle Scholar
  187. Sherman, K.E., Rouster, S.D., Chung, R.T., Rajicic, N. (2002). Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clinical Infectious Diseases, 34: 831–837.PubMedGoogle Scholar
  188. Sherman, M., Bain, V., Villeneuve, J-P., Myers R.P., Cooper, C., Martin, S., Lowe, C. (2004). The management of chronic viral hepatitis: A Canadian consensus conference 2004. Canadian Journal of Gastroenterology, 18: 715–728.PubMedGoogle Scholar
  189. Shiffman, M.L., Diago, M., Tran, A., Pockros, P., Reindollar, R., Prati, D., Rodriguez-Torres, M., Lardelli, P., Blotner, S., Zeuzem, S. (2006). Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clinical Gastroenterology and Hepatology, 4: 645–652.PubMedGoogle Scholar
  190. Shiffman, M.L., DiBisceglie, A.M., Lindsay, K.L, Morishima, C., Wright, E.C., Everson, G.T., Lok, A.S., Morgan, T.R., Bonkovsky, H.L., Lee, W.M., Dienstag, J.L., Ghany, M.G., Goodman, Z.D., Everhart, J.E., and the HALT-C Trial Group (2004). Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 126: 1015–1023.PubMedGoogle Scholar
  191. Shiffman, M.L., Price, A., Hubbard, S. (2005). Treatment of chronic hepatitis C virus (HCV) genotype 1 with peg interferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and epoetin alfa (EPO) enhances sustained virologic response (SVR). Program and abstracts of the 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, San Francisco, CA. Abstract 55.Google Scholar
  192. Siebert, U., Sroczynski, G., Rossol, S., Wasem, J., Ravens-Sieberer, U., Kurth, B.M., Manns, M.P., McHutchison, J.G., Wong, J.B., German Hepatitis C Model (GEHMO) Group, International Hepatitis Interventional Therapy (IHIT) Group. (2003). Gut, 52: 425–432.PubMedGoogle Scholar
  193. Singh, N., Gayowski, T., Wannstedt, C.F., Shakil, A.O., Wagener, M.M., Fung, J.J., Marino, I.R. (1998). Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial. Transplantation, 65: 82–86.PubMedGoogle Scholar
  194. Sonnenblick, M., Rosenmann, D., Rosin, A. (1990). Reversible cardiomyopathy induced by interferon. BMJ, 300: 1174–1175.PubMedGoogle Scholar
  195. Soriano, V., Puoti, M., Sulkowski, M. (2004b). Care of patients with hepatitis C and HIV co-infection. AIDS, 18: 1–12.Google Scholar
  196. Soriano, V., Nunez, M., Camino, N., Maida, I., Barreiro, P., Romero, M., Martin-Carbonero, L., Garcia-Samaniego, J., Gonzalez-Lahoz, J. (2004a). Hepatitis C virus-RNA clearance in HIV-co-infected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antiviral Therapy, 9 : 505–509.Google Scholar
  197. Soriano, V., Perez-Olmeda, M., Rios, P., Nunez, M., Garcia-Samaniego, J., Gonzalez-Lahoz, J. (2004b). Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Research Human Retroviruses, 20: 351–354.Google Scholar
  198. Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39: 1147–1171.PubMedGoogle Scholar
  199. Su, X., Rhodes, S., Yee, L., Im, K., Tong, X., Howell, C., Haritos, M., Liang, T.J., Taylor, M.W., Yang, H. (2006). Association of interferon signaling pathway and interferon stimulated genes with response to pegylated interferon and ribavirin therapy in HCV infected Caucasian and African American patients. Gastroenterology, 130 (4 Suppl 2): A-748; abstract 2.Google Scholar
  200. Sugano, S., Suzuki, T., Watanabe, M., Ohe, K., Ishii, K., Okajima, T. (1998). Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. American Journal of Gastroenterology, 93: 2441–2444.PubMedGoogle Scholar
  201. Sulkowski, M., Moore, R., Mehta, S., Chaisson, R., Thomas, D. (2002). Hepatitis C and progression of HIV disease. JAMA, 288: 199–206.PubMedGoogle Scholar
  202. Sulkowski, M.S., Thomas, D.L. (2003). Hepatitis C in the HIV-infected person. Annals of Internal Medicine, 138: 197–207.PubMedGoogle Scholar
  203. Sulkowski, M.S., Dieterich, D.T., Bini, E.J., Brau, N., Alvarez, D., DeJesus, E., Leitz, G.J. for the HIV/HCV Coinfection Study Group. (2005a). Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: A randomized controlled trial. Journal of AIDS, 39: 504–506.Google Scholar
  204. Sulkowski, M.S., Mast, E.E., Seeff, L.B., Thomas, D.L. (2000). Hepatitis C virus infection as anopportunistic disease in persons infected with human immunodeficiency virus. Clinical Infectious Diseases, 30 (Suppl 1): S77–S84.PubMedGoogle Scholar
  205. Sulkowski, M.S., Wright, T., Rossi, S.J., Arora, S., Lamb, M., Wang, K., Gries, J.M., Yalamanchili, S. (2005b). Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C infection undergoing methadone maintenance therapy. Clinical and Pharmacological Therapy, 77: 214–224.Google Scholar
  206. Sulkowski, M.S. (2006). Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. Journal of Hepatology, 44: S49–S55.PubMedGoogle Scholar
  207. Sullivan, P.S., Hanson, D.L., Teshale, E.H., Wotring, L.L., Brooks, J.T. (2006). Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS, 20: 1171–1179.PubMedGoogle Scholar
  208. Sullivan, S.D., Jensen, D.M., Bernstein, D.E., Hassanein, T.I., Foster, G.R., Lee, S.S., Cheinquer, H., Craxi, A., Cooksley, G., Klaskala, W., Pettit, K., Patel, K.K., Green, J. (2004). Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology, 99: 1490–1496.PubMedGoogle Scholar
  209. Swain, M.G., Foster, G., Hadziyannis, S., Heathcote, J., Jensen, D., Lee, S., Pockros, P., Sulkowski, M., Trepo, C. (2005). Clustering of poor prognostic factors in heavier patients with chronic hepatitis C (CHC): Baseline characteristics and outcomes with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV, COPEGUS®) in randomized, international, Phase III trials. Hepatology, 42 (Suppl 1): 687A; abstract 1244.Google Scholar
  210. Taliani, G., Gemignani, G., Ferrari, C., Aceti, A., Bartolozzi, D., Blanc, P.L., Capanni, M., Esperti, F., Forte, P., Guadagnino, V., Mari, T., Marino, N., Milani, S., Pasquazzi, C., Rosina, F., Tacconi, D., Toti, M., Zignego, A.L., Messerini, L., Stroffolini, T., the Nonresponder Retreatment Group. (2006). Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology, 130: 1098–1106.PubMedGoogle Scholar
  211. Tam, R.C., Pai, B., Bard, J., Lim, C., Averett, D.R., Ohan, U.T., Milovanovic, T. (1999). Ribavirin polarizes human T cell responses towards and Type 1 cytokine profile. Journal of Hepatology, 30: 376–382.PubMedGoogle Scholar
  212. Tang, K.H., Hermann, E., Cooksley, H., Tatman, N., Chokshi, S., Williams, R., Zeuzem, S., Naoumov, N.V. (2005). Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. Journal of Hepatology, 43: 776–782.PubMedGoogle Scholar
  213. Tedaldi, E.M., Baker, R.K., Moorman, A.C., Alzola, C.F., Furhrer, J., McCabe, R.E., Wood, K.C., Holmberg, S.D., the HIV Outpatient Study (HOPS) Investigators. (2003). Influence of co infection with HCV on morbidity and mortality due to HIV infection in the era of HAART. Clinical Infectious Diseases, 36: 363–367.PubMedGoogle Scholar
  214. Torriani, F., Rodriguez-Torres, M., Rockstroh, J., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U.M., Dieterich. D.T., for the APRICOT Study Group. (2004). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351: 438–450.PubMedGoogle Scholar
  215. Veteran’s Health Administration (2005). Management and treatment of hepatitis C virus infection in HIV-infected adults: Recommendations from the Veteran’s Affairs Hepatitis C Resource Center Program and national Hepatitis C Program Office. American Journal of Gastroenterology, 100: 2338–2354.Google Scholar
  216. Vogel, M., Baumgarten, A., Klausen, G. (2006). Pegylated interferon in the treatment of acute HCV infection in HIV positive individuals—Interim analysis of a large German multicenter study. Program and abstracts of the 2nd International Workshop on HIV and Viral Hepatitis Coinfection, January 12-14, Amsterdam, The Netherlands. Abstract 25.Google Scholar
  217. Vogel,W., Ferenci, P., Fontana, R. (2002). Peginterferon alfa-2a (40KD) (PEGASYS®) in liver transplant recipients with established recurrent hepatitis C: Interim results of an ongoing randomized multicenter trial. Hepatology, 36: 312A; abstract 596.Google Scholar
  218. Voigt, E., Schulz, C., Klausen, G., Goelz, J., Mauss, S., Schmutz, G., Jessen, H., Weitner, L., Mutz, A., Schranz, D., Rockstroh, J.K., for the KAAD Study Group. (2006). Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Journal of Infection, 53: 36–42.PubMedGoogle Scholar
  219. Von Wagner, M., Huber, M., Berg, T., Hinrichsen, H., Rasenack, J., Heintges, T., Bergk, A., Bernsmeier, C., Häussinger, D., Herrmann, E., Zeuzem, S. (2005). Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 129: 522–527.Google Scholar
  220. Wang, Y.S., Youngster, S., Bausch, J., Zhang, R., McNemar, C., Wyss, D.F. (2000). Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry, 39: 10634–10640.PubMedGoogle Scholar
  221. Wills, R.J. (1990). Clinical pharmacokinetics of interferons. Clinical Pharmacokinetics, 19: 390–399.PubMedGoogle Scholar
  222. Wills, R.J., Dennis, S., Speigel, H.E., Gibson, D.M., Nadler, P.I. (1984). Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clinical and Pharmacological Therapy, 35: 722–727.Google Scholar
  223. Wirth, S., Pieper-Boustani, H., Lang, T., Ballauff, A., Kullmer, U., Gerner, P., Wintermeyer, P., Jenke, A. (2005). Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology, 41: 1013–1018.PubMedGoogle Scholar
  224. Yoshida, E., Heathcote, J., Bailey, R., Anderson, F., Kaita, K., Krajden, M., Deschênes, M., Bain, V., Lee, S., Sherman, M., Peltekian, K., Simonyi, S. (2005). “Real” world experience with peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C: Results of a multicenter open-label expanded access program in Canada. Gastroenterology, 128 (4 Suppl 2): A-723; abstract S1572.Google Scholar
  225. Zanini, B., Puoti, M., Quiros-Roldan, E. (2006). The optimal duration of treatment for HIV-infected patients with chronic hepatitis C and genotype 2 or 3 is 48 weeks: Results of a randomized controlled trial. Program and abstracts of the 2nd International Workshop on HIV and Viral Hepatitis Coinfection; January 12-14, Amsterdam, The Netherlands. Abstract 27.Google Scholar
  226. Zarski, J-P., Smith, C., Hadziyannis, S.J., Rakela, J., Hassanein, T., Lee, S.-D. (2005). Are there differences in baseline characteristics or treatment outcomes with peginterferon α-2a (40kDa) and ribavirin in patients infected with HCV genotype 1a versus 1b. Journal of Hepatology, 42 (Suppl 2): 228; abstract 624.Google Scholar
  227. Zehnter, E., Mauss, S., John, C., Heyne, R., Möller, B., Lutz, T., Bokemeyer, B., Kihn, R., Moog, G., Alshuth, U., Hüppe, D. (2006). Efficacy and safety of peginterferon alpha-2a (40 KD) [PEG] plus ribavirin [RBV] 1000/1200 mg/d in genotype 1 patients with chronic hepatitis C and “normal” ALT levels. Journal of Hepatology, 44 (Suppl 2): S231; abstract 622.Google Scholar
  228. Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J., Ibranyi, E., Weiland, O., Noviello, S., Brass, C., Albrecht, J. (2006b). Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 44; 97–103.Google Scholar
  229. Zeuzem, S., Diago, M., Gane, E., Reddy, K.R., Pockros, P., Prati, D., Shiffman, M., Farci, P., Gitlin, N., O’Brien, C.B., Lamour, F., Lardelli, P., for the PEGASYS Study NR16071 Investigator Group. (2004a). Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology, 127: 1724–1732.Google Scholar
  230. Zeuzem, S., Feinman, S.V., Rasenack, J., Heathcote, E.J., Lai, M-Y., Gane, E., O’Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman J., Brunda, M.J. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine, 343: 1666–1672.PubMedGoogle Scholar
  231. Zeuzem, S., Herrmann, E, Lee, J-H., Fricke, J., Neumann, A.U., Modi, M., Colucci, G., Roth, K. (2001). Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a. Gastroenterology, 120: 1438–1447.PubMedGoogle Scholar
  232. Zeuzem, S., Hultcrantz, R., Bourlier, M., Goeser, T., Marcellin, P., Sanchez-Tapias, J., Sarrazin, C., Harvey J., Brass C., Albrecht, J. (2004b). Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. Journal of Hepatology, 40: 993–999.Google Scholar
  233. Zeuzem, S., Pawlotsky, J.-M., Lukasiewicz, E., von Wagner, M., Goulis, I., Lurie, Y., Gianfranco, E., Vrolijk, J-M., Esteban, J.I., Hexode, C., Latgging, M., Negro, F., Soulier, A., Verheij-Hart, E., Hansen, B., Tal, R., Ferrari, C., Schalm, S.W., Neumann, A.U., for the DITTO-HCV Study Group. (2005). International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology, 43: 250–257.Google Scholar
  234. Zeuzem, S., Sarrazin, C., Wagner, F., Rouzier, R., Forestier, N., Gupta, S., Hussain, M., Shah, A., Cutler, D., Zhang, J. (2006a) The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFN α-2b in the treatment of HCV-1 PEG-IFN α-2b non-responders: Antiviral activity and HCV variant analysis. Journal of Hepatology, 44 (Suppl 2): S35; abstract 78.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • S. James Matthews
  • Christopher McCoy

There are no affiliations available

Personalised recommendations